These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy. Barreiro P; Labarga P; de Mendoza C; Benítez-Gutiérrez L; Fernandez-Montero JV; Peña JM; Soriano V Antivir Ther; 2016; 21(6):489-494. PubMed ID: 26887981 [TBL] [Abstract][Full Text] [Related]
44. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Bräu N Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996 [TBL] [Abstract][Full Text] [Related]
45. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice. Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706 [TBL] [Abstract][Full Text] [Related]
46. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164 [TBL] [Abstract][Full Text] [Related]
47. Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. González-Colominas E; Broquetas T; Retamero A; García-Retortillo M; Cañete N; Coll S; Pellicer R; Giménez MD; Cabrero B; Bory F; Knobel H; Salas E; Solà R; Carrión JA Liver Int; 2015 May; 35(5):1557-65. PubMed ID: 25385188 [TBL] [Abstract][Full Text] [Related]
48. New hepatitis C therapies for special patient populations. Soriano V; Labarga P; de Mendoza C; Fernández-Montero JV; Esposito I; Benítez-Gutiérrez L; Peña JM; Barreiro P Expert Opin Pharmacother; 2016; 17(2):217-29. PubMed ID: 26595348 [TBL] [Abstract][Full Text] [Related]
49. Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. Behzadpour D; Ahmadi Vasmehjani A; Mousavi Nasab SD; Ahmadi NA; Baharlou R Pathog Glob Health; 2016; 110(7-8):310-315. PubMed ID: 27830997 [TBL] [Abstract][Full Text] [Related]
50. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. Piroth L; Paniez H; Taburet AM; Vincent C; Rosenthal E; Lacombe K; Billaud E; Rey D; Zucman D; Bailly F; Bronowicki JP; Simony M; Diallo A; Izopet J; Aboulker JP; Meyer L; Molina JM; Clin Infect Dis; 2015 Sep; 61(5):817-25. PubMed ID: 25977266 [TBL] [Abstract][Full Text] [Related]
51. Clinically Significant Drug-Drug Interactions Between Hepatitis C Virus and HIV Treatments. Kiser JJ Top Antivir Med; 2016; 24(3):106-110. PubMed ID: 27841981 [TBL] [Abstract][Full Text] [Related]
52. Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions. Chan J; Chung RT Clin Pharmacol Drug Dev; 2017 Mar; 6(2):147-163. PubMed ID: 28263458 [TBL] [Abstract][Full Text] [Related]
53. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms. Cooper CL; Klein MB HIV Med; 2014 Nov; 15(10):621-4. PubMed ID: 24802099 [TBL] [Abstract][Full Text] [Related]
54. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756 [TBL] [Abstract][Full Text] [Related]
55. Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients. Rice DP; Ordoveza MA; Palmer AM; Wu GY; Chirch LM AIDS Care; 2018 Dec; 30(12):1507-1511. PubMed ID: 30021452 [TBL] [Abstract][Full Text] [Related]
57. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. Soriano V; Sherman KE; Rockstroh J; Dieterich D; Back D; Sulkowski M; Peters M AIDS; 2011 Nov; 25(18):2197-208. PubMed ID: 21866039 [TBL] [Abstract][Full Text] [Related]
58. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745 [TBL] [Abstract][Full Text] [Related]
59. Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir. Ramirez ML; Vargas FX; González-Garcia J; Quereda C; Pérez-Elías MJ; de Cea AM; Barros C; Condés E; Moreno JS; Santos I; Torralba M; Aldamiz-Echevarria T; Moreno A AIDS; 2014 Oct; 28(16):2487-9. PubMed ID: 25265233 [No Abstract] [Full Text] [Related]
60. Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals. Griesbeck M; Valantin MA; Lacombe K; Samri-Hassimi A; Bottero J; Blanc C; Sbihi Z; Zoorob R; Katlama C; Guiguet M; Altfeld M; Autran B; AIDS; 2017 Jun; 31(9):1223-1234. PubMed ID: 28492391 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]